High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
January 22nd, 2019
A high throughput protocol for functional assessment of HIV efficient reactivation and clearance of latent proviruses is described and applied by testing the impact of interventions on HIV transcription and splicing. Representative results of the effect of latency reversing agents on LTR-driven transcription and splicing are provided.
Overview
This article describes a high throughput protocol for assessing the functional impact of latency reversing agents (LRAs) on HIV transcription and splicing. The method allows for simultaneous evaluation of LRA effects on HIV mRNA processing, providing insights into virus reactivation and clearance of latent proviruses.
Key Study Components
Area of Science
- Neuroscience
- Virology
- Molecular Biology
Background
- HIV latency poses a significant challenge in treatment.
- Latency reversing agents are being explored for their potential to reactivate latent HIV.
- Understanding HIV transcription and splicing is crucial for developing effective therapies.
- This study aims to provide a reliable method for assessing LRA effects.
Purpose of Study
- To evaluate the impact of LRAs on HIV mRNA processing.
- To assess the ability of LRAs to induce virus reactivation.
- To provide a high throughput method for functional assessment.
Methods Used
- Cell cultivation in a 96-well plate format.
- Use of a dual color reporter construct for monitoring transcription.
- Assessment of LRA effects on LTR-driven transcription and splicing.
- Analysis of results to determine the efficacy of LRAs.
Main Results
- Demonstrated the ability of LRAs to enhance HIV transcription.
- Provided evidence of LRA effects on splicing mechanisms.
- Showed potential for clearing latent HIV reservoirs.
- Results support further investigation into LRA applications.
Conclusions
- The protocol offers a reliable method for assessing LRA efficacy.
- Findings contribute to understanding HIV latency and reactivation.
- Future studies may expand on these results to improve HIV treatment strategies.
Frequently Asked Questions
Executive Industry Relevance
This high-throughput in vitro method enables biopharma teams to efficiently evaluate latency reversing agents (LRAs) for HIV cure strategies by simultaneously measuring transcriptional and splicing reactivation. The dual-color reporter system provides quantitative, flow cytometry-based readouts that support mechanistic de-risking of LRAs in preclinical discovery. By integrating viability assessment, the approach informs go/no-go decisions on compound efficacy and toxicity early in the pipeline.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses on HIV latency reversal by measuring LRA-induced changes in unspliced and spliced HIV transcripts.
- Operational Value: Enables rapid screening of LRAs in adherent and suspension cells using a standardized 96-well format.
- Predictive Value: Supports portfolio triage by identifying compounds that coordinately activate transcription and splicing, indicative of functional provirus reactivation.
Screening & Assay Development
- Scientific Value: Delivers simultaneous, multiplexed readouts of HIV transcription (EGFP) and splicing (DsRed) from a single LTR-driven reporter.
- Operational Value: Compatible with high-throughput workflows, allowing testing of large LRA libraries with minimal reagent consumption.
- Assay Readiness: Includes built-in compensation controls and viability staining to ensure data quality and reduce false positives from cytotoxic compounds.
Translational & Preclinical Research
- Translational Continuity: Generates mechanistic data on LRA effects on HIV mRNA processing that informs ex vivo validation in primary cell models.
- Preclinical De-risking: Provides quantitative thresholds for splicing and transcription activation to prioritize LRAs with favorable mechanistic profiles.
- Predictive Confidence: Enables assessment of LRA synergy in combination studies, supporting dose-reduction strategies to mitigate toxicity.
Pipeline & Workflow Integration
The method fits within the HIV discovery continuum from early target validation through lead optimization, offering a functional bridge between biochemical screening and phenotypic validation in relevant cellular contexts.
- Discovery Biology: Supports hypothesis testing on LRA mechanisms by quantifying effects on HIV transcriptional bursting and splicing fidelity.
- Screening: Delivers reproducible, quantitative fluorescence readouts suitable for assay miniaturization and automation in drug discovery campaigns.
- Analytics: Enables statistical comparison of LRA conditions via flow cytometry metrics such as percentage of double-positive cells and splicing ratios.
- Translational Research: Produces mechanistic biomarkers (transcription/splicing activation) that correlate with reservoir perturbation in ex vivo systems.
- Enterprise Reuse: Establishes a reusable platform for evaluating novel LRAs, combinations, or resistance variants across HIV strains.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in LRA action by decoupling transcription from splicing effects.
- Operational Value: Standardizes assessment across laboratories through defined transfection, incubation, and staining parameters.
- Strategic Value: Improves capital efficiency by filtering ineffective LRAs before costly in vivo studies.
- Portfolio Impact: Enables risk-adjusted advancement decisions based on dual-parameter efficacy and toxicity profiles.
Implementation Considerations
- Requires expertise in mammalian cell transfection and flow cytometry compensation.
- Dependent on access to fluorescence microscopes or flow cytometers with FITC and PE detection channels.
- Necessitates standardization of reagent handling to ensure consistent lipid-DNA complex formation across wells.
- Involves optimization of LRA working concentrations to avoid cytotoxicity confounding transcriptional readouts.
- Limited to cell lines amenable to transfection; primary cell adaptation requires additional validation.
Biopharma FAQs
Chapters in this video
0:04
Title
0:32
Transfection of HEK293T Cells with Dual Color Reporter Construct
2:01
Treatment of Transfected HEK293T Cells with Latency Reversing Agents
2:33
Staining of Transfected Cells with Fixable Viability Dye for Flow Cytometry Analysis
4:40
EGFP and DsRed Measurements by Flow Cytometry and Data Analysis
5:49
Results: Assessment of Latency Reversing Agents on HIV Transcription and Splicing
6:43
Conclusion
